ELR-CXC chemokine antagonism in neutrophilic inflammation

中性粒细胞炎症中 ELR-CXC 趋化因子拮抗作用

• 批准号: 227099-2008
• 负责人: Gordon, John
• 金额: $ 2.11万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=393401
• 关键词: ELR; CXC; chemokine; antagonism; neutrophilic

While we understand the basic biology of numerous individual inflammatory molecules in the body, we have yet to generate a reasoned overview of how they interact with each other. Anecdotal evidence suggests that there exists a much greater interdependence of these functions than previously appreciated. We have developed a new anti-inflammatory drug, called G31P, that blocks an entire class of inflammatory molecules, and so is highly effective as an anti-inflammatory drug. In fact, it is much more effective than we would have predicted, so we wish to know exactly how it works in blocking the activities of other classes of inflammatory molecules. We have some evidence that is also blocks processes not traditionally thought of as inflammatory (e.g., the spread of cancer cells through the body). We will use a combination of test tube and live animals studies with lab animals, pre-clinical studies with experimental pigs, and clinical studies with dogs with melanoma tumours to investigate these issues. Overall, these studies are designed allow us to develop G31P for veterinary uses as diverse as pneumonia, arthritis, and cancer.

虽然我们了解体内众多单个炎症分子的基本生物学，但我们还没有对它们如何相互作用产生一个合理的概述。坊间证据表明，这些职能之间的相互依赖性比以前认识到的要大得多。我们已经开发出一种新的抗炎药，称为G31P，它可以阻断整个类别的炎症分子，因此作为一种抗炎药是非常有效的。事实上，它比我们预测的要有效得多，所以我们想确切地知道它是如何阻断其他类别的炎症分子的活动的。我们有一些证据也可以阻止传统上认为不是炎症性的过程(例如，癌细胞在体内的传播)。我们将使用试管和活体动物研究相结合的方法，对实验室动物进行研究，对实验猪进行临床前研究，对患有黑色素瘤的狗进行临床研究，以研究这些问题。总体而言，这些研究旨在使我们能够开发用于肺炎、关节炎和癌症等多种兽医用途的G31P。